Our development portfolio includes novel oncology and supportive care product candidates.

* In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups
** In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration

Upon successful development and regulatory approval of any of our product candidates we intend to make them available to cancer patients in North America, Europe and China through our own commercialization efforts and to establish a network of licensees and distributors in other geographic areas.


Clinical Trials

The links below will provide you with information regarding TESARO's ongoing clinical trials.

  • Rolapitant

    Three Phase 3 Studies in CINV (completed):
    NCT01500226
    NCT01500213
    NCT01499849

  • Niraparib

    A Phase 3 Ovarian Cancer Maintenance Treatment Study (NOVA):
    NCT01847274

    A Phase 3 Study in Germline BRCA Mutation-Positive Breast Cancer Patients (BRAVO):
    NCT01905592

    A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens (QUADRA):
    NCT02354586

    Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in Platinum-Sensitive Ovarian Cancer (AVANOVA):
    NCT02354131

  • For Medical Information
    Requests Only:


    Click here to request Medical Information
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue